Company Overview of GlobeImmune Inc.
GlobeImmune Inc. operates as a biopharmaceutical company. The company develops and manufactures Tarmogens, a molecular immunotherapy vaccine for the treatment of cancer and infectious diseases. Its products include GI-4000 for pancreas, non-small cell lung, colorectal, endometrial, and ovarian cancers, as well as melanoma and multiple myeloma; GI-6207 for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Tarmogen used for the treatment of lung, breast, colon, bladder, kidney, ovary, uterus, and prostate cancers; and GS-4774 a therapeutic vaccine for chronic HBV infection. GlobeImmu...
1450 Infinite Drive
Louisville, CO 80027
Founded in 1995
Key Executives for GlobeImmune Inc.
Chief Executive Officer
Total Annual Compensation: $388.1K
Principal Financial & Accounting Officer
Total Annual Compensation: $191.5K
Vice President of Corporate Development
Total Annual Compensation: $188.8K
Compensation as of Fiscal Year 2013.
GlobeImmune Inc. Key Developments
GlobeImmune Inc. Announces Earnings Results for the Quarter and Nine Months Ended September 30, 2014
Nov 12 14
GlobeImmune Inc. announced earnings results for the quarter and nine months ended September 30, 2014. For the quarter, the company reported net loss of $6.4 million compared to $0.7 million a year ago.
For the nine months the company reported net loss of $14.5 million compared to $1.2 million a year ago. The increase in the net losses was primarily due to non-cash interest expense and early retirement associated with convertible notes and fair-value adjustments of warrants. These non-cash expenses terminated upon closing of the initial public offering.
Globeimmune Announce Updated Results from Eleven Chordoma Patients in the GI-6301 Phase 1 Trial
Oct 17 14
GlobeImmune Inc. announced that updated results from eleven chordoma patients in the GI-6301 Phase 1 trial were presented at the 2014 CTOS Annual Meeting in Berlin, Germany. Christopher R. Heery, M.D., Head, Clinical Trials Group, Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI) presented the data during his talk entitled "NCI Experience Using Yeast-Brachyury Vaccine (GI-6301) in Patients with Advanced Chordoma (Paper 030)". The GI-6301 Tarmogen(R) product candidate targets cancers containing the brachyury protein. The NCI is conducting a Phase 1 safety, immunology and early efficacy trial of GI-6301 monotherapy in patients with late-stage cancers known to express the brachyury protein including chordoma. This presentation updates data GlobeImmune previously reported on seven chordoma patients in the trial. Results to date from the eleven chordoma patients in this trial include: GI-6301 has been generally well tolerated, immunogenic, and has shown evidence of clinical activity in both advanced epithelial cancers and chordomas. Summary results: One confirmed partial response by RECIST that has continued past one year. Eight patients with stable disease at day 85 restaging; Two of these patients had stable disease at study entry; Study status; Seven of 11 chordoma patients have left the study due to disease progression; Four of 11 chordoma patients remain on treatment with stable disease; Three of these four patients had progressive disease at study entry; 62% of all patients (all tumor types) evaluated to date in this Phase 1 trial had post-administration brachyury-specific T cell immune responses; The most common adverse events seen in this trial were mild/moderate injection site reactions.
Pennina Safer Resigns as Member of Board of Directors of GlobeImmune, Inc
Oct 3 14
On September 30, 2014, GlobeImmune Inc. announced that Dr. Pennina Safer was resigning from her position as a member of GlobeImmune’s board of directors, including her position as a member of the Nominating and Corporate Governance Committee thereof, effective as of September 30, 2014.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 31, 2014